267 related articles for article (PubMed ID: 14996519)
1. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.
Curtis SP; Ng J; Yu Q; Shingo S; Bergman G; McCormick CL; Reicin AS
Clin Ther; 2004 Jan; 26(1):70-83. PubMed ID: 14996519
[TBL] [Abstract][Full Text] [Related]
2. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
[TBL] [Abstract][Full Text] [Related]
3. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
[TBL] [Abstract][Full Text] [Related]
5. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
[TBL] [Abstract][Full Text] [Related]
6. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
Curtis SP; Ko AT; Bolognese JA; Cavanaugh PF; Reicin AS
Curr Med Res Opin; 2006 Dec; 22(12):2365-74. PubMed ID: 17265571
[TBL] [Abstract][Full Text] [Related]
7. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
8. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.
Ramey DR; Watson DJ; Yu C; Bolognese JA; Curtis SP; Reicin AS
Curr Med Res Opin; 2005 May; 21(5):715-22. PubMed ID: 15974563
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
van der Heijde D; Baraf HS; Ramos-Remus C; Calin A; Weaver AL; Schiff M; James M; Markind JE; Reicin AS; Melian A; Dougados M
Arthritis Rheum; 2005 Apr; 52(4):1205-15. PubMed ID: 15818702
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Reicin AS; Shapiro D; Sperling RS; Barr E; Yu Q
Am J Cardiol; 2002 Jan; 89(2):204-9. PubMed ID: 11792343
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
[TBL] [Abstract][Full Text] [Related]
12. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study.
Meek IL; Vonkeman HE; Kasemier J; Movig KL; van de Laar MA
Eur J Clin Pharmacol; 2013 Mar; 69(3):365-71. PubMed ID: 22890587
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.
Patrignani P; Capone ML; Tacconelli S
Expert Opin Pharmacother; 2003 Feb; 4(2):265-84. PubMed ID: 12562317
[TBL] [Abstract][Full Text] [Related]
14. Safety of etoricoxib in patients with reactions to NSAIDs.
Quercia O; Emiliani F; Foschi FG; Stefanini GF
J Investig Allergol Clin Immunol; 2008; 18(3):163-7. PubMed ID: 18564626
[TBL] [Abstract][Full Text] [Related]
15. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Krum H; Curtis SP; Kaur A; Wang H; Smugar SS; Weir MR; Laine L; Brater DC; Cannon CP
Eur J Heart Fail; 2009 Jun; 11(6):542-50. PubMed ID: 19380329
[TBL] [Abstract][Full Text] [Related]
16. Etoricoxib.
Cochrane DJ; Jarvis B; Keating GM
Drugs; 2002; 62(18):2637-51; discussion 2652-3. PubMed ID: 12466002
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Cannon CP; Curtis SP; Bolognese JA; Laine L;
Am Heart J; 2006 Aug; 152(2):237-45. PubMed ID: 16875903
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
Krueger K; Lino L; Dore R; Radominski S; Zhang Y; Kaur A; Simpson R; Curtis S
Ann Rheum Dis; 2008 Mar; 67(3):315-22. PubMed ID: 17965424
[TBL] [Abstract][Full Text] [Related]
19. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
Kristensen LE; Jakobsen AK; Askling J; Nilsson F; Jacobsson LT
Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1137-49. PubMed ID: 25623277
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]